Interferon-complement loop in transplant-associated thrombotic microangiopathy.

Area of Science:

• Hematology
• Immunology
• Genomics

Background:

• Transplant-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic stem cell transplantation (HSCT).
• While eculizumab targets complement, not all TA-TMA patients respond, necessitating research into other injury mechanisms.
• TA-TMA serves as a model for studying thrombotic microangiopathies.

Purpose of the Study:

• To investigate the molecular pathways involved in TA-TMA pathogenesis after HSCT.
• To compare complement pathway activation in TA-TMA with other thrombotic microangiopathies like atypical hemolytic uremic syndrome (aHUS).
• To explore the relationship between interferon signaling and complement activation in TA-TMA.

Main Methods:

• Transcriptome analysis of peripheral blood mononuclear cells from children undergoing HSCT.
• Samples were collected before HSCT, at TA-TMA onset, and after TA-TMA resolution.
• Gene expression and regulatory network analyses were performed.

Main Results:

• TA-TMA showed significant upregulation of classical, alternative, and lectin complement pathways.
• Interferon signaling, including STAT1 and STAT2, was notably increased in TA-TMA.
• Gene expression normalized after eculizumab therapy, supporting its discontinuation upon TA-TMA resolution.
• Complement activation in TA-TMA involves multiple pathways, unlike the predominantly alternative pathway in aHUS.

Conclusions:

• TA-TMA involves a complex interplay of multiple complement pathways and interferon signaling.
• An "interferon-complement loop" may drive endothelial injury in TA-TMA.
• Findings suggest potential for novel combined anti-complement and anti-interferon therapies for TA-TMA and related microangiopathies.